HIV and RPR Testing at 28 Weeks Gestational Age
HIV and RPR testing at 28 weeks (early third trimester) is recommended specifically for high-risk pregnant women to detect new infections acquired during pregnancy, allowing time for treatment to prevent vertical transmission and reduce devastating fetal and neonatal outcomes including stillbirth, congenital syphilis, and perinatal HIV transmission.
Rationale for Third-Trimester Screening
Syphilis (RPR) Testing at 28 Weeks
The CDC, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and American Academy of Family Physicians all recommend repeat syphilis screening at 28 weeks for specific populations 1:
High-risk criteria requiring 28-week rescreening:
- Women living in high-prevalence areas (particularly southern United States and certain metropolitan areas)
- Uninsured women or those living in poverty
- Sex workers
- Illicit drug users
- Hispanic and African-American populations (higher prevalence)
- Women with prior positive first-trimester results
- Women not previously tested
- Communities with high syphilis morbidity
Why 28 weeks matters: Early intervention (first and second trimester) reduces adverse outcomes by more than half compared to third-trimester treatment 2. The odds ratio for any adverse pregnancy outcome is 2.24 when treatment occurs in the third trimester versus earlier 2. Testing at 28 weeks provides a critical window to detect seroconversion during pregnancy while still allowing adequate time for penicillin treatment to prevent congenital syphilis, stillbirth, and neonatal complications.
HIV Testing at 28 Weeks
Third-trimester HIV retesting is recommended for high-risk women, though emerging evidence supports broader application 3:
High-risk criteria requiring third-trimester HIV rescreening:
- Women in the 22 states with elevated HIV incidence
- Facilities with prenatal HIV prevalence ≥1 per 1,000
- Women at high risk of acquiring HIV (incarcerated, high-risk sexual behavior, injection drug use)
- Women with signs/symptoms of acute HIV
Critical timing consideration: Approximately 80% of perinatal HIV transmissions occur after 36 weeks' gestation 4. Testing at 28 weeks allows time to:
- Initiate antiretroviral therapy before the highest-risk transmission period
- Reduce transmission risk from 25% to 10% with timely intervention 3
- Plan appropriate delivery management
Heterosexual intercourse is the most common HIV transmission route in reproductive-age women, and HIV seroconversion risk is actually higher during pregnancy than outside pregnancy 4.
Clinical Implementation Algorithm
For ALL pregnant women:
- Initial screening at first prenatal visit (both HIV and syphilis)
At 28 weeks, rescreen if ANY of the following apply:
For Syphilis:
- High-prevalence geographic area
- Uninsured or living in poverty
- History of substance use
- Sex work involvement
- Previous STI diagnosis
- Hispanic or African-American ethnicity in high-prevalence areas
For HIV:
- Resides in one of 22 states with elevated incidence
- Facility prenatal HIV prevalence ≥1/1,000
- Ongoing high-risk behavior
- New or multiple sexual partners during pregnancy
Additional screening at delivery is recommended for both infections in high-risk women who tested negative at 28 weeks 1, 5.
Common Pitfalls to Avoid
- Missing seroconversion during pregnancy: Women can acquire both infections during pregnancy; a negative first-trimester test does not guarantee continued negative status 5
- Assuming low risk: Many women with new infections during pregnancy were not identified as "high-risk" initially 4
- Delayed treatment: Testing too late in pregnancy (after 28 weeks) reduces treatment efficacy for preventing adverse outcomes 2
- Lost to follow-up: High-risk populations are often transient; testing at routine 28-week visits captures women who might not return for delivery 5, 6
Evidence Quality Note
The syphilis screening recommendations are based on strong guideline consensus from multiple major organizations (USPSTF, CDC, AAP, ACOG, AAFP) with reaffirmed evidence of substantial net benefit 1. The HIV recommendations come from established Public Health Service guidelines 3, though recent evidence suggests consideration for universal third-trimester testing rather than risk-based approaches 4.